

RECENT ADVANCES IN UNDERSTANDING AND TREATING CHRONIC MYELOID NEOPLASMS



UNIVERSITÀ
DEGLI STUDI
FIRENZE

PROMOTED BY:



FONDAZIONE
INTERNAZIONALE
MENARINI

Florence (Italy)

SEPTEMBER

8th - 10th | 2016

Aula Magna

Università degli Studi di Firenze

Florence

PROGRAMME

Organised by:

Università degli Studi di Firenze
Azienda Ospedaliera Universitaria Careggi

President of the Meeting:

Alessandro Maria Vannucchi

Dipartimento di Medicina Sperimentale e Clinica
dell'Università degli Studi di Firenze

Scientific Secretariat:

Paola Guglielmelli
Lisa Pieri



Introduction

The conference entitled "Recent Advances in Understanding and Treating Myeloid Neoplasms", that will be held at the University of Florence from 8 to 10 September 2016, holds the promise to be a very successful event for the growing community of researchers and clinicians involved in the field, and we do hope it will attract as well as colleagues from related basic and clinical disciplines. This convention happens just 10 years after the discovery of the first recurrent mutation in JAK2 in patients with chronic myeloproliferative neoplasms and 5 years after the approval of the first JAK2 inhibitor for the treatment of myelofibrosis. Remarkably, it took as long as 50 years of efforts to shed light on the molecular basis of these disorders after the original theorization by W. Dameshek in 1951. Many of the scientists and clinicians that have been instrumental in this process will intervene to the conference presenting the latest news and discussing the next steps. Indeed, although we now know a lot of these disorders and are able to more effectively managing them and improving the quality of life of the patients, much remains to be understood and the ultimate goal of a cure still appears sadly far.

The knowledge accumulated in the last years in chronic myeloid neoplasms is an excellent example of how basic researchers, research scientists and clinicians can successfully collaborate and integrate their own skills to generate new approaches for understanding the molecular basis of diseases, improving diagnosis, refining prognostication methods and developing a framework for innovative therapies.

On behalf of the scientific committee, the speakers and chairs, I look forward to welcome you in Florence for a very productive conference.

President of the Meeting
Prof. Alessandro Maria Vannucchi

WITH THE PATRONAGE OF



UNIVERSITÀ
DEGLI STUDI
FIRENZE

Università degli Studi di Firenze



Rendiamo il cancro sempre più curabile.

Associazione Italiana per la Ricerca
sul Cancro (AIRC)



Società Italiana di Ematologia (SIE)

Società Italiana di Ematologia
Sperimentale (SIES)



GITMO

GRUPPO ITALIANO PER IL TRAPIANTO DI MIDOLLO OSSEO, CELLULE STAMINALI EMPORETICHE E TERAPIA CELLULARE

Gruppo Italiano Trapianti di Midollo
Osseo (GITMO)

President of the Meeting: Alessandro Maria Vannucchi
Scientific Secretariat: Paola Guglielmelli, Lisa Pieri

PROMOTED BY:

**Fondazione
Internazionale Menarini**

Edificio L - Strada 6 Centro
Direzionale Milanofiori
I-20089 Rozzano (Milan, Italy)
Phone: +39 02 55308110
Fax: +39 02 55305739
E-mail: milan@fondazione-menarini.it
www.fondazione-menarini.it

ORGANISING SECRETARIAT
AND CME PROVIDER:

**AVEC S.r.l. - Incentive Paintings -
Angela Volpe**

Via Lavoratori Autobianchi, 1
c/o Polo Tecnologico Brianza
Edificio 9 - Ufficio 14
I-20832 Desio (MB), Italy
Phone: +39 0362 581579
Fax: +39 0362 1860074
E-mail: angela.volpe@avec-eventi.com
claudia.cislaghi@avec-eventi.com

- PROGRAMME -

Thursday, September 8TH, 2016

Afternoon

02.30 p.m. - 03.00 p.m.	A. Vannucchi (Florence, I), L. Dei (Florence, I), M. Calamai (Florence, I) <i>Introduction</i>
03.00 p.m. - 03.15 p.m.	A. Casini (Florence, I) WELCOME ADDRESSES
Chairperson:	A. Vannucchi (Florence, I)
03.15 p.m. - 04.00 p.m.	T. Barbui (Bergamo, I) OPENING LECTURE: FITTING MPN DIAGNOSIS WITHIN THE WHO CRITERIA

Session I: Seed and Soil

Chairpersons:	R. Lemoli (Genoa, I), L. Pieri (Florence, I)
04.00 p.m. - 04.30 p.m.	A. Migliaccio (New York, US) <i>The stem cell of origin of MPN</i>
04.30 p.m. - 05.00 p.m.	S. Mèndez-Ferrer (Cambridge, UK) <i>The microenvironment of MPN</i>
05.00 p.m. - 05.30 p.m.	M.C. Le Bousse Kerdiles (Villejuif, FR) <i>Cytokines and inflammation in MPN</i>
05.30 p.m. - 06.00 p.m.	S. Constantinescu (Brussels, B) <i>Receptors and signaling</i>
06.00 p.m.	Welcome Ceremony

Friday, September 9TH, 2016

Morning

Session II: The mutational landscape of MPN (I)

Chairpersons: G. Specchia (Bari, I), A.M. Vannucchi (Florence, I)	
09.00 a.m. – 09.30 a.m.	R. Kralovics (Wien, A) <i>The mutational landscape of MPN</i>
09.30 a.m. – 10.00 a.m.	W. Vainchenker (Villejuif, FR) <i>Calreticulin mutations: a new paradigm of disease?</i>
10.00 a.m. – 10.30 a.m.	N. Cross (Southampton, UK) <i>Germline alleles that predispose to MPN</i>
10.30 a.m. – 11.00 a.m.	R. Skoda (Basel, CH) <i>Clonal complexity and clonal progression in MPN</i>
11.00 a.m. – 11.30 a.m.	Coffee Break

Session III: The mutational landscape of MPN (II)

11.30 a.m. – 12.00 p.m.	P. Guglielmelli (Florence, I) <i>Mutations and prognosis</i>
12.00 p.m. – 12.30 p.m.	J. Prchal (Salt Lake, US) <i>Clonal hematopoiesis of indeterminate potential</i>
12.30 p.m. – 01.00 p.m.	I. Roberts (Oxford, UK) <i>Transient myeloproliferative disorders</i>
01.00 p.m. – 02.00 p.m.	Buffet Lunch

Friday, September 9TH, 2016

Afternoon

Session IV: The path to Target therapy

Chairpersons:	A. Bosi (Florence, I), A. Rambaldi (Bergamo, I)
02.00 p.m. - 02:30 p.m.	A. Mullally (Boston, US) <i>Targets for targeted therapy</i>
02.30 p.m. - 03.00 p.m.	G. Barosi (Pavia, I) <i>How to best design novel clinical trials</i>
03.00 p.m. - 03.30 p.m.	F. Passamonti (Varese, I) <i>How to best select patients for clinical trials</i>
03.30 p.m. - 04.00 p.m.	J. J. Kiladjan (Paris, FR) <i>How to use at best JAK inhibitors</i>
04.00 p.m. - 04.30 p.m.	Coffee break
04.30 p.m. - 05.00 p.m.	A. Tefferi (Rochester, US) <i>Novel drugs outside JAK inhibitors</i>
05.00 p.m. - 05.30 p.m.	A. Reiter (Mannheim, D) <i>Mastocytosis and eosinophilias</i>
05.30 p.m. - 06.00 p.m.	F. Lo Coco (Rome, I) <i>Target therapy: Lessons from acute leukemia</i>

Saturday, September 10TH, 2016

Morning

Session V: Myelodysplastic syndromes and leukemia

Chairpersons:	R. Foà (Rome, I), M. Cazzola (Pavia, I)
09.00 a.m. – 09.30 a.m.	M. Cazzola (Pavia, I) <i>The mutational landscape of MDS</i>
09.30 a.m. – 10.00 a.m.	E. Solary (Villejuif, FR) <i>Mutations and targets in CMML</i>
10.00 a.m. – 10.30 a.m.	V. Santini (Florence, I) <i>Targeted agents for MDS</i>
10.30 a.m. – 11.00 a.m.	C. Mecucci (Perugia, I) <i>Germline alleles that predispose to leukemia</i>
11.00 a.m. – 11.30 a.m.	Coffee break
11.30 a.m. – 12.30 a.m.	F.S. Mennini (Rome, I) LECTURE: SUSTAINABLE DRUG DEVELOPMENT AND USE IN ONCOHEMATOLOGY
12.30 a.m. – 01.30 p.m.	GENERAL DISCUSSION AND CONCLUDING REMARKS
01.30 p.m. – 02.30 p.m.	Brunch

- General Information -

MEETING VENUE

Aula Magna - Università degli Studi di Firenze
Piazza San Marco, 4 50100 Firenze

REGISTRATION HOURS:

Thursday, September 8th: 01.30 p.m. to 06.00 p.m.
Friday, September 9th: 08.00 a.m. to 06.00 p.m.
Saturday, September 10th: 08.00 a.m. to 02.30 p.m.

OFFICIAL LANGUAGE

English. Simultaneous translation will not be provided.

REGISTRATIONS

No registration fee is required to attend the Conference.
Please return the registration form to:
AVEC S.r.l. - Incentive Paintings - Angela Volpe
Via Lavoratori Autobianchi, 1 - c/o Polo Tecnologico Brianza -
Edificio 9 - Ufficio 14 - I-20832 Desio (MB, Italy)
Phone: +39 0362 581579
Fax: +39 0362 1860074
E-mail: angela.volpe@avec-eventi.com
claudia.cislaghi@avec-eventi.com

CONGRESS WEBSITE

www.MyeloidNeoplasms-Florence2016.avec-eventi.com

CME ACCREDITATION

The application for CME accreditation has been submitted for Italian Physicians. The CME credits will be awarded only after attendance of all sessions. Completion of the Registration Form, the Learning & Assessment questionnaires are compulsory.

- General Information -

EUROPEAN ACCREDITATION

An application has been submitted to the EACCME for CME accreditation of this event.

TECHNICAL FACILITIES

A Slide Center with PCs (Windows and Macintosh operating systems) will be available for Speakers to preview and finalize their presentations. Speakers are kindly requested to submit their presentations on USB flash drive to the Slide Center technicians at least one hour before their talks.

SLIDE CENTRE OPENING HOURS:

Thursday, September 8th: 01.30 p.m. to 06.00 p.m.
Friday, September 9th: 08.00 a.m. to 06.00 p.m.
Saturday, September 10th: 08.00 a.m. to 02.30 p.m.

LUNCHES AND COFFEE BREAKS

Lunches and coffee breaks will be served in the Meeting area.

ABSTRACTS BOOK

Participants will receive the Abstract book at the Meeting.

ATTENDANCE CERTIFICATE

The attendance certificate will be issued at the accreditation desk following full attendance at the Conference.

- FACULTY -

Tiziano BARBUI

Professor of Hematology
Scientific Director, Research Foundation
Ospedale Papa Giovanni XXIII
Bergamo (Italy)

Giovanni BAROSI

Center for the Study of Myelofibrosis
IRCCS Policlinico S. Matteo Foundation
Pavia, (Italy)

Alberto BOSI

Department of Hematology
University of Florence
Florence (Italy)

Monica CALAMAI

Director of the "Azienda Ospedaliero
Universitaria Careggi"
Florence (Italy)

Mario CAZZOLA

Department of Hematology and Oncology
IRCCS Policlinico San Matteo Foundation
Pavia (Italy)

Stefan CONSTANTINESCU

Ludwig Institute for Cancer Research
Brussels (Belgium)

Nicholas CROSS

University of Southampton
Southampton (United Kingdom)

Luigi DEI

Dean of the University of Florence
Florence (Italy)

Roberto FOA'

Professor of Hematology - Head, Division of
Hematology - University "Sapienza"
Rome (Italy)

Paola GUGLIELMELLI

Department of Experimental and Clinical
Medicine - University of Florence
Hematology Unit - Azienda Ospedaliera
Universitaria Careggi
Florence (Italy)

Jean-Jacques KILADJIAN

Department of Hematology
Saint-Louis Hospital
Paris (France)

Robert KRALOVICS

CeMM - Research Center for Molecular Me-
dicine of the Austrian Academy of Sciences
Wien (Austria)

Marie Caroline LE BOUSSE-KERDILES

Inserm UMR-S-MD1197
Villejuif (France)

Roberto LEMOLI

Professor of Hematology
Department of Internal Medicine (Di.M.I.)
University of Genoa - IRCCS S. Martino - IST
Genova (Italy)

Francesco LO COCO

Professor of Hematology
University Tor Vergata
Rome (Italy)

Cristina MECUCCI

Department of Medicine
University of Perugia
Perugia (Italy)

Simón MENDEZ-FERRER

Department of Hematology
University of Cambridge
Cambridge (United Kingdom)

Francesco Saverio MENNINI

Research Director
Centre for Economic Evaluation and HTA
(EEHTA)
President
ISPOR Italy Chapter - Rome
Faculty of Economics and Faculty of Science -
University of Rome Tor Vergata
Faculty of Statistics, University of Rome
La Sapienza
Kingston University, London, UK
Rome (Italy)

- FACULTY -

Annarita MIGLIACCIO

Professor of Medicine
Division of Hematology/Oncology Department
of Medicine Mount Sinai School of Medicine
New York (United States of America)

Ann MULLALLY

Department of Hematology
Brigham and Women's Hospital
Boston (United States of America)

Francesco PASSAMONTI

Hematology Director
University of Insubria
Ospedale di Circolo e Fondazione Macchi
Varese (Italy)

Lisa PIERI

Department of Experimental and Clinical
Medicine
University of Florence
Department of Hematology
Azienda Ospedaliero Universitaria Careggi
Florence (Italy)

Josef PRCHAL

The Charles A. Nugent, M.D., and Margaret
Nugent Professor
University of Utah
Salt Lake (United States of America)

Alessandro RAMBALDI

Hematology and Bone Marrow Transplant Unit
ASST Papa Giovanni XXIII
Bergamo (Italy)

Andreas REITER

Department of Hematology and Oncology
UMM Universitätsmedizin Mannheim
Mannheim (Germany)

Irene ROBERTS

Professor of Paediatric Haematology
University of Oxford
Oxford (United Kingdom)

Valeria SANTINI

Associate Professor of Hematology
Hematology Unit-AOU Careggi
University of Florence
Florence (Italy)

Radek SKODA

Department of Biomedicine
University Hospital Basel
Basel (Switzerland)

Eric SOLARY

Department of Research
Gustave Roussy Institute
Paris (France)

Giorgina SPECCHIA

Department of Emergency and
of Organs Transplant
Policlinico di Bari
Bari (Italy)

Ayalew TEFFERI

Department of Hematology
Mayo Clinic
Rochester (United States of America)

William VAINCHENKER

INSERM U1170
Gustave-Roussy Institute
Villejuif (France)

Alessandro Maria VANNUCCHI

Department of Experimental and Clinical
Medicine
University of Florence
Azienda Ospedaliera-Universitaria Careggi
Florence (Italy)

A special thank to :
Novartis Farma S.p.A.
Janssen-Cilag S.p.A.
For the unconditional financial support

- Notes -

A series of 25 horizontal dashed lines for writing notes.





Fondazione Internazionale Menarini
Symposia n: 291